Skip to main content

Table 4 Schedule of exploratory assessments

From: A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy

  1. CTL cytotoxic T lymphocyte, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer QLQ-C30, EQ-5D-5 L: EuroQol 5 dimensions 5 levels, HLA human leukocyte antigen, MSI microsatellite instability, QOL quality of life, WT1 Wilms’ tumor gene 1
  2. Performed in specific trial sites where the tests are available. Informed consent is obtained from each patient before performing any tests